Samuele Cazzamalli | Group Head of Small Molecule

Samuele Cazzamalli, Group Head of Small Molecule, Philochem

Samuele Cazzamalli studied Medicinal Chemistry at the University of Milan. During his doctoral studies at ETH Zürich in the group of Prof. Dario Neri (2015-2018), Samuele has generated novel Antibody-Drug Conjugate, Small Molecule-Drug Conjugate and Small Molecule-Radio Conjugate products for applications in oncology.
Samuele heads now the Small Molecule Therapeutics R&D unit at Philochem AG (Switzerland), focusing on the development of products based on small organic ligands for tumor-targeting applications.


Festival of Biologics Day 1 @ 14:00

Small Molecule Therapeutics targeting Fibroblast Activation Protein in the tumor microenvironment of solid tumors

  • OncoFAP is a clinically validated small organic ligand targeting FAP in solid tumors
  • OncoFAP-drug and -radio conjugates selectively accumulate to tumors in vivo
  • OncoFAP-drug and OncoFAP-radio conjugates potently induce anti-tumor response at doses below tumor saturation both in monotherapy and in combination with immunotherapy
last published: 30/Jun/22 09:37 GMT

back to speakers